Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors
- 9 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 69 (10), 1819-1826
- https://doi.org/10.1007/s00228-013-1532-6
Abstract
Our aim was to describe all serious cutaneous adverse drug reactions (ADRs) spontaneously reported in France for all oral protein kinase inhibitors, their characteristics and whether they were labeled (reported in the Summary of Product Characteristics) or not. We performed a retrospective observational study in the French PharmacoVigilance Database, selecting for analysis serious cutaneous reactions of patients due to treatment with oral protein kinase inhibitors (erlotinib, gefitinib, imatinib, nilotinib, dasatinib, sunitinib, sorafenib, pazopanib, lapatinib, everolimus) between 1 January 2008 and 31 December 31 2010. Ninety-four patients suffered from 115 serious cutaneous reactions due to oral protein kinase inhibitors. Serious cutaneous reactions more frequently reported were maculo-papular rash (mostly with imatinib), followed by hand–foot syndrome (specifically with sorafenib) and papulopustular rash (particularly with erlotinib). Patients were mostly males (63 %) with a mean age of 62.6 ± 15.4 years. Drug withdrawal was observed in 73.1 % of cases because of these cutaneous reactions. Delay of occurrence of the ADR varied from 11.5 to 58.5 days. Unlabeled serious reactions were found (17.4 %), including skin ulceration, vasculitis or purpura with sorafenib or sunitinib and drug rash with eosinophilia and systemic symptoms with imatinib. Some of the serious ADRs spontaneously reported with oral protein kinase inhibitors are labeled and commonly reported in the literature, but others occur only rarely and unlabeled. In our study, most serious ADRs occurred in males within the 2 first months of treatment and were responsible for the withdrawal of therapy with protein kinase inhibitors.Keywords
This publication has 32 references indexed in Scilit:
- Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case ReportCase Reports in Oncology, 2011
- Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular CarcinomaAnnals of Dermatology, 2011
- Comparison of Three Methods (Consensual Expert Judgement, Algorithmic and Probabilistic Approaches) of Causality Assessment of Adverse Drug ReactionsDrug Safety, 2010
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBritish Journal of Dermatology, 2009
- Chemotherapeutic agents and the skin: An updateJournal of the American Academy of Dermatology, 2008
- Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical ManagementThe Oncologist, 2007
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under‐reporting on odds ratiosStatistics in Medicine, 2002
- The Medical Dictionary for Regulatory Activities (MedDRA)Drug Safety, 1999